Emily Hoppes

Emily Hoppes

Auto-generated profile, based on publicly available information

Emily Hoppes

FHI 360

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2022 in Gates Open Research
Verified
Journal Article
Open access
PDF file
EHEmily Hoppes
Emily Hoppes
CNChukwuemeka Nwachukwu
Chukwuemeka Nwachukwu
JHJulie Hennegan
Julie Hennegan
DBDiana L. Blithe
Diana L. Blithe
ACAmanda Cordova-Gomez
Amanda Cordova-Gomez
LRLillian Rountree
Lillian Rountree
Background: Contraceptive-induced menstrual changes (CIMCs) can affect family planning (FP) users’ lives in both positive and negative ways, resulting in both opportunities and consequences. Despite this, and despite the important links between FP and menstrual health (MH), neither field adequately addresses CIMCs, including in research, product development, policies, and programs globally. Methods: In November 2020, a convening of both MH and FP experts reviewed the existing evidence on CIMCs and identified significant gaps in key areas. Results: These gaps led to the establishment of a CIMC Task Force in April 2021 and the development of the Global Research and Learning Agenda: Building Evidence on Contraceptive-Induced Menstrual Changes in Research, Product Development, Policies, and Programs Globally (the CIMC RLA) , which includes four research agendas for (1) measurement, (2) contraceptive research and development (R&D) and biomedical research, (3) social-behavioral and user preferences research, and (4) programmatic research. Conclusions: Guided by the CIMC RLA, researchers, product developers, health care providers, program implementers, advocates, policymakers, and funders are urged to conduct research and implement strategies to address the beneficial and negative effects of CIMCs and support the integration of FP and MH. CIMCs need to be addressed to improve the health and well-being of women, girls, and other people who menstruate and use contraceptives globally. Disclaimer : The views expressed in this article are those of the authors. Publication in Gates Open Research does not imply endorsement by the Gates Foundation.

25 September 2023 in Global Health: Science and Practice
Verified
Journal Article
Open access
PDF file
EHEmily Hoppes
Emily Hoppes
KRKate H. Rademacher
Kate H. Rademacher
LWLucy Wilson
Lucy Wilson
TMTanya Dargan Mahajan
Tanya Dargan Mahajan
KWKatrina Wilson
Katrina Wilson
ELEva Lathrop
Eva Lathrop
Key Messages The family planning (FP) and menstrual health (MH) fields share goals and areas of work, serve similar populations, and have the potential to learn from and enhance one another, but they are not effectively integrated, which can result in missed opportunities to improve individuals’ health, well-being, and dignity. Integrating FP and MH ensures that both FP and MH commodities and services are provided under a single programmatic umbrella that may include both same-day, co-located services and referral-based approaches. Potential ways to integrate FP and MH include (1) improving education and awareness; (2) integrating delivery of FP and MH commodities and services within health systems; (3) improving integrated counseling on FP and MH; (4) including evidence-based methods that rely on menstrual tracking in FP method provision; (5) addressing the issue of menstrual status as a barrier to FP; (6) including contraceptives as an option for managing menstrual disorders and pain; (7) implementing social and behavior change communication and advocacy for stakeholder engagement; and (8) strengthening national policies and guidelines.

5 April 2024 in medRxiv
Verified
Preprint
Open access
PDF file
AMAmelia C.L. Mackenzie
Amelia C.L. Mackenzie
SCStephanie Chung
Stephanie Chung
EHEmily Hoppes
Emily Hoppes
AMAlexandria K. Mickler
Alexandria K. Mickler
ACAlice F. Cartwright
Alice F. Cartwright
Despite the importance of menstruation and the menstrual cycle to health, human rights, and sociocultural and economic wellbeing, the study of menstrual health suffers from a lack of funding, and research remains fractured across many disciplines. We sought to systematically review validated approaches to measure four aspects of changes to the menstrual cycle—bleeding, blood, pain, and perceptions—caus ed by any source and used within any field. We then evaluated the measure quality and utility for clinical trials of the identified instruments. We searched MEDLINE, Embase, and four instrument databases and included peer-reviewed articles published between 2006 and 2023 that reported on the development or validation of instruments assessing menstrual changes using quantitative or mixed-methods methodology. From a total of 8,490 articles, 8,316 were excluded, yielding 174 articles reporting on 94 instruments. Almost half of articles were from the United States or United Kingdom and over half of instruments were only in English, Spanish, French, or Portuguese. Most instruments measured bleeding parameters, uterine pain, or perceptions, but few assessed characteristics of blood. Nearly 60% of instruments were developed for populations with menstrual or gynecologic disorders or symptoms. Most instruments had fair or good measure quality or clinical trial utility; however, most instruments lacked evidence on responsiveness, question sensitivity and/or transferability, and only three instruments had good scores of both quality and utility. Although we took a novel, transdisciplinary approach, our systematic review found important gaps in the literature and instrument landscape, pointing towards a need to examine the menstrual cycle in a more comprehensive, inclusive, and standardized way. Our findings can inform the development of new or modified instruments, which—if used across the many fields that study menstrual health and within clinical trials—can contribute to a more systemic and holistic understanding of menstruation and the menstrual cycle.

5 April 2024 in medRxiv
Verified
Preprint
Open access
PDF file
AMAmelia C. L. Mackenzie
Amelia C. L. Mackenzie
SCStephanie Chung
Stephanie Chung
EHEmily Hoppes
Emily Hoppes
NMNora Miller
Nora Miller
ABAnne E. Burke
Anne E. Burke
OVOlivia Vandeputte
Olivia Vandeputte
Objective We sought to develop consensus recommendations for improved measurement of contraceptive-induced menstrual changes (CIMCs) in contraceptive clinical trials to build upon previous standardization efforts. Study Design We undertook a virtual consensus-building process using a modified Delphi approach, incorporating aspects of Nominal Group Technique and the Jandhyala method. The process consisted of four half-day meetings, developing recommendations within five topical working groups, a series of consensus questionnaires to assess recommendation agreement on a 4-point Likert-like scale, and opportunities for input and feedback throughout the process. Recommendations required at least 75% consensus to be included. Results Our interdisciplinary group—from 26 organizations and 13 countries in five global regions across academia, nonprofit research organizations, the pharmaceutical industry, and funding agencies— developed 44 consensus recommendations. These included recommendations on standardization, patient-reported outcome measure development aligned with current regulatory guidance, trial design, protocol development, participant recruitment, data collection, data analysis, and areas for exploratory research. Seven recommendations were deemed a priority by over 85% of our group. Conclusion Using a formal consensus-building process, we reached high levels of agreement around recommendations for more standardized and patient-centered measurement of CIMCs in contraceptive clinical trials, now and in the future. Implications statement Consensus recommendations on measuring bleeding changes and related outcomes in contraceptive clinical trials can improve reporting of standardized, patient-centered outcomes in future product labeling. These improvements can enable providers to offer more relevant counseling on contraceptives and permit greater comparability and data synthesis across trials to inform clinical guidance.


30 May 2026 in medRxiv
Verified
Preprint
Open access
PDF file
AMAmelia Mackenzie
Amelia Mackenzie
JSJenni Smit
Jenni Smit
MMMarija Miric
Marija Miric
AEAlison Edelman
Alison Edelman
MBMags Beksinska
Mags Beksinska
BZBongiwe Zulu
Bongiwe Zulu
Objective: To address the need for improved measurement of the ways contraception impacts the baseline menstrual cycle (i.e., contraceptive-induced menstrual changes; CIMCs) by assembling an interdisciplinary, global research collective to rigorously develop a person-centered measure for CIMCs in multiple languages. As the first step, this paper reports on our conceptual model development, which is the foundation for ongoing measure development. Study design: We conducted 18 focus groups with 106 people experiencing CIMCs while using hormonal or intrauterine contraception in Durban, South Africa, Santo Domingo, Dominican Republic, and Portland Oregon, United States. We used a virtual affinity mapping approach to analyze qualitative data, which was the basis of our conceptual model along with relevant theory and related models in the literature. Results: The conceptual model of experiences with CIMCs depicts the baseline menstrual cycle, including CIMCs and conceptually-linked effects and the impacts and perceptions of those CIMCs. We found key domains of changes in pain, bleeding volume, bleeding patterns, and characteristics of blood. Conclusion: Our CIMC conceptual model will inform development of a measure with evidence of validation across three language and global contexts. Adoption of a person-centered, standardized CIMC measurement across trials will improve knowledge and decision-making between methods. Implications: Defining an evidenced-based conceptual model for CIMCs expands our understanding of how contraceptive users experience and understand menstruation and CIMCs. We can use this model to improve and standardize measurement of CIMCs.